New Delhi, February 7: Union Minister Dr. Jitendra Singh urged states to establish “BioE3 Cells” as part of India’s push towards a biotechnology revolution, aiming to achieve the Bio-Vision for Viksit Bharat by 2047. Speaking at the “Centre-State Conclave” on BioE3 Policy at Vigyan Bhavan, the Minister emphasized the importance of fostering collaboration between the Centre and the states to enhance India’s bioeconomy and future growth.
Dr. Singh encouraged state governments to utilize their distinctive strengths, resources, and economic objectives to advance India’s biomanufacturing sector. He particularly highlighted the potential of marine resources and the unique assets found in the Himalayan region, along with other bio-resources that can contribute to a new biotech wave.
The Union Minister, who oversees various portfolios including Science and Technology, Earth Sciences, and the PMO, credited Prime Minister Narendra Modi’s forward-thinking leadership for the prompt approval of the BioE3 Policy as part of the government’s agenda within its first 100 days in office. He referenced other significant initiatives such as Mission Mausam, funding for Space Startups, and the National Research Foundation (NRF).
To ensure the effective execution of the BioE3 Policy, Dr. Singh called for the establishment of ‘BioE3 Cells’ in partnership with the Centre through the Department of Biotechnology (DBT). These cells are envisioned to serve as vital knowledge hubs, connecting state and national stakeholders to facilitate the policy’s successful implementation. Operating at the state level, the BioE3 Cells will function as central platforms for knowledge sharing, policy alignment, and technology integration within the biomanufacturing industry.
During the conclave, Dr. Singh unveiled a booklet outlining the establishment of BioE3 Cells aimed at promoting collaborations between the Centre and the states to drive biotech innovations. He stressed that the primary aim of these cells is to ensure that biomanufacturing initiatives align closely with the specific priorities and resources of each state, while remaining connected to national objectives. By establishing a comprehensive network of BioE3 Cells across the country, the government intends to integrate emerging technologies, innovative research, and sustainable practices within the biomanufacturing sector.
Reiterating PM Modi’s “Whole of Government” strategy, Dr. Singh called for robust collaboration between the Centre and the states to ensure the BioE3 Policy’s successful rollout. He emphasized the necessity to move away from isolated efforts and instead work collectively across various sectors, clearly differentiating purposes among industry, academia, and entrepreneurship. He also highlighted successful platforms like IN-SPACe and BIRAC that have fostered valuable partnerships with the private sector.
Additionally, Dr. Singh noted significant advancements in India’s biotechnology field, such as the domestically developed DNA vaccine during the pandemic, the antibiotic ‘Nafithromycin’, and successful gene therapy trials conducted at CMC Vellore. He reaffirmed India’s openness to partnering with the private sector, aiming to replicate successes similar to those in the space and nuclear energy sectors.
In expressing the government’s commitment, Dr. Singh pointed out recent budget allocations for Bio Foundries and Biomanufacturing, marking a significant shift under PM Modi from traditional populist approaches towards a focus on science and technology. He cited examples of effective Centre-State cooperation, including initiatives like pairing states facing similar challenges to enhance collaborative problem-solving, as well as funding for lake cleanup projects such as Loktak Lake and Dal Lake. Furthermore, he highlighted the establishment of Fecal Sludge Treatment Plants (FSTP) during the Kumbh Mela, showcasing the critical role of science and biotechnology in addressing everyday challenges and promoting sustainable development.
Dr. Rajesh Gokhale, Secretary of the Department of Biotechnology, spoke at the conclave about the opportunities in the biotech sector for achieving a Viksit Bharat. Dr. Alka Sharma, Senior Advisor at DBT, summarized the discussions held throughout the day among participating states. Kiran Mazumdar Shaw, founder of Biocon, contributed her insights virtually, while R. Subramani, Founder of Fermbox Bio, also attended, alongside senior representatives from nearly all states. Dr. Jitendra Kumar, MD of BIRAC, shared his organization’s efforts to bolster industry connections, paving the way for the establishment of BioE3 Cells.
The conclave provided an essential platform for senior representatives from various states to discuss biotechnology initiatives, ensuring these efforts are aligned with the unique strengths and resources of each state, while remaining true to the overarching goals of the BioE3 Policy.
